Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare Obesity Treatment topic
No spam. Unsubscribe anytime.
House approves limited obesity-treatment bill after debate over GLP-1 coverage and costs
Summary
The House passed Senate Bill 48 after amendments narrowed its scope. Sponsors sought coverage expansion for behavioral therapies, diabetes-prevention programs and bariatric surgery in large-group plans and left optional employer coverage for GLP-1 medications; opponents warned of large cost and premium increases.
The Colorado House on May 5 passed a narrowed version of Senate Bill 48, a health bill that initially pursued broad insurance coverage of obesity treatments and diabetes prevention measures.
"This bill will make sure that large group health plans are required to cover behavioral health therapies, the National Diabetes Prevention Program, and medical nutrition therapy," Representative Brown, a co-prime sponsor, told members. The final measure requires coverage of certain behavioral and clinical services and bariatric surgery in designated large-group plans, but sponsors removed a Medicaid mandate and the bill no longer requires all insurers to cover GLP-1 medications; instead the final text allows large-group plans to offer the option to purchase coverage for at least one FDA-approved GLP-1 medication.
Debate on the floor focused on costs and program design. Representative Bradley offered Amendment L020, intended to add a pre-surgery accountability requirement — a patient food diary for bariatric surgery candidates — arguing taxpayers and insurers should have safeguards because coverage could raise premiums. "If my premiums have to go up 8%, I don't want you eating a Taco Bell," Bradley said. The amendment failed after floor debate.
Opponents, including Representative Johnson and the minority caucus, warned the new coverage pathway could increase premiums and strain public budgets. Representative Johnson cited examples from other states and published analyses about rapid cost increases tied to demand for anti-obesity medications and warned of higher filings for the Department of Insurance.
Sponsors argued the package had been narrowed to avoid a fiscal note and to protect state employee plans, and said the bill's required services would address escalating obesity-related health risks and long-term costs. Representative Mabry, another co-prime sponsor, said the bill had been scaled back to remove Medicaid from the mandate and to make coverage optional in some private markets.
Why it matters: The legislation expands access to behavioral and clinical obesity interventions through certain employer-sponsored group plans while leaving politically contested drug-coverage decisions optional. Floor debate highlighted competing priorities between public-health goals and near-term fiscal constraints.
What happens next: The bill passed the House and will go to the governor. Legislators and advocates said further work will be needed to monitor cost impacts and consider future changes to Medicaid or state employee plan coverage.
